$15.55
1.33% yesterday
Nasdaq, Sep 04, 10:00 pm CET
ISIN
US4923271013
Symbol
KROS

Keros Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Keros Therapeutics Inc Classifications & Recommendation:

Buy
65%
Hold
35%

Keros Therapeutics Inc Price Target

Target Price $22.95
Price $15.55
Potential
Number of Estimates 10
10 Analysts have issued a price target Keros Therapeutics Inc 2026 . The average Keros Therapeutics Inc target price is $22.95. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 11 Analysts recommend Keros Therapeutics Inc to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Keros Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Keros Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 3.55 201.62
2,266.67% 5,579.44%
EBITDA Margin -5,904.23% -0.39%
94.76% 99.99%
Net Margin -5,277.46% -0.98%
94.83% 99.98%

13 Analysts have issued a sales forecast Keros Therapeutics Inc 2025 . The average Keros Therapeutics Inc sales estimate is

$202m
Unlock
. This is
13.41% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$262m 12.47%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $3.6m 2,266.67%
2025
$202m 5,579.44%
Unlock
2026
$5.1m 97.47%
Unlock
2027
$13.7m 169.22%
Unlock
2028
$63.0m 359.02%
Unlock
2029
$101m 60.88%
Unlock
2030
$116m 14.60%
Unlock
2031
$221m 90.12%
Unlock
2032
$288m 30.36%
Unlock

3 Analysts have issued an Keros Therapeutics Inc EBITDA forecast 2025. The average Keros Therapeutics Inc EBITDA estimate is

$-796k
Unlock
. This is
147.64% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-819k 149.04%
Unlock
, the lowest is
$-764k 145.77%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-210m 23.93%
2025
$-796k 99.62%
Unlock
2026
$-125m 15,584.62%
Unlock
2027
$-83.2m 33.30%
Unlock

EBITDA Margin

2024 -5,904.23% 94.76%
2025
-0.39% 99.99%
Unlock
2026
-2,446.80% 627,284.62%
Unlock
2027
-606.21% 75.22%
Unlock

13 Keros Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Keros Therapeutics Inc net profit estimate is

$-2.0m
Unlock
. This is
110.50% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$53.3m 184.02%
Unlock
, the lowest is
$-168m 997.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-187m 22.46%
2025
$-2.0m 98.95%
Unlock
2026
$-190m 9,527.92%
Unlock
2027
$-190m 0.14%
Unlock
2028
$-121m 36.43%
Unlock
2029
$-75.4m 37.55%
Unlock
2030
$-70.8m 6.14%
Unlock
2031
$660k 100.93%
Unlock
2032
$3.1m 365.15%
Unlock

Net Margin

2024 -5,277.46% 94.83%
2025
-0.98% 99.98%
Unlock
2026
-3,718.99% 379,388.78%
Unlock
2027
-1,383.43% 62.80%
Unlock
2028
-191.59% 86.15%
Unlock
2029
-74.37% 61.18%
Unlock
2030
-60.92% 18.09%
Unlock
2031
0.30% 100.49%
Unlock
2032
1.06% 253.33%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.00 -0.05
3.85% 99.00%
P/E negative
EV/Sales negative

13 Analysts have issued a Keros Therapeutics Inc forecast for earnings per share. The average Keros Therapeutics Inc EPS is

$-0.05
Unlock
. This is
110.87% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.31 184.78%
Unlock
, the lowest is
$-4.15 1,002.17%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.00 3.85%
2025
$-0.05 99.00%
Unlock
2026
$-4.67 9,240.00%
Unlock
2027
$-4.68 0.21%
Unlock
2028
$-2.97 36.54%
Unlock
2029
$-1.86 37.37%
Unlock
2030
$-1.74 6.45%
Unlock
2031
$0.02 101.15%
Unlock
2032
$0.08 300.00%
Unlock

P/E ratio

Current 33.80 446.61%
2025
-320.95 1,049.44%
Unlock
2026
-3.33 98.96%
Unlock
2027
-3.33 0.00%
Unlock
2028
-5.23 57.06%
Unlock
2029
-8.38 60.23%
Unlock
2030
-8.92 6.44%
Unlock
2031
952.82 10,781.84%
Unlock
2032
206.01 78.38%
Unlock

Based on analysts' sales estimates for 2025, the Keros Therapeutics Inc stock is valued at an EV/Sales of

-0.29
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.25 100.01%
2025
-0.29 16.36%
Unlock
2026
-11.50 3,853.25%
Unlock
2027
-4.27 62.85%
Unlock
2028
-0.93 78.21%
Unlock
2029
-0.58 37.84%
Unlock
2030
-0.50 12.74%
Unlock
2031
-0.27 47.40%
Unlock
2032
-0.20 23.28%
Unlock

P/S ratio

Current 2.71 99.96%
2025
3.13 15.48%
Unlock
2026
123.84 3,853.31%
Unlock
2027
46.00 62.86%
Unlock
2028
10.02 78.21%
Unlock
2029
6.23 37.84%
Unlock
2030
5.44 12.74%
Unlock
2031
2.86 47.40%
Unlock
2032
2.19 23.29%
Unlock

Current Keros Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 08 2025
B of A Securities
Locked
Locked
Locked Jun 10 2025
Wedbush
Locked
Locked
Locked May 30 2025
Scotiabank
Locked
Locked
Locked May 12 2025
HC Wainwright & Co.
Locked
Locked
Locked May 08 2025
Truist Securities
Locked
Locked
Locked Apr 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 01 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 08 2025
Locked
B of A Securities:
Locked
Locked
Jun 10 2025
Locked
Wedbush:
Locked
Locked
May 30 2025
Locked
Scotiabank:
Locked
Locked
May 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 08 2025
Locked
Truist Securities:
Locked
Locked
Apr 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today